Circadian Technologies
(ASX:CIR) CEO and managing director, Robert Klupacs updates listeners on the medical technology's operations. He says the recent clearance from the US Food and Drug Administration to trial VGX-100, a cancer treatment drug designed to starve tumours and halt their growth, has key opinion leaders worldwide "very very excited" after after "tremendous results" from pre-trial clinical testing.
Klupacs also gives an update on Circadian's relationships with Healthscope, Cincinnati Children's Hospital Medical Centre, Eli Lily and Ark Therapeutics, and outlines the company's focus for 2012.
